22 Mar

Analysts Are Mostly Positive on BioMarin Pharmaceutical in March

WRITTEN BY Margaret Patrick

Analysts’ recommendations and target price

Wall Street analysts expect a potential upside of 32.04% for BioMarin Pharmaceutical (BMRN) based on the stock’s closing price on March 21.

Analysts first revised the company’s target price downward from $120.59 in January to $119.65 in February but then raised it to $119.87 in March. The current consensus analyst recommendation for the stock is a “buy.”

Analysts Are Mostly Positive on BioMarin Pharmaceutical in March

Of the 26 analysts covering BioMarin Pharmaceutical, ten have given it “strong buys,” ten have given it “buys,” and six have given it “holds.” The highest target price estimate for the company is $165, and the lowest is $81.

On March 21, BioMarin Pharmaceutical closed at $90.78, 0.91% higher than its previous closing price, 19.75% higher than its 52-week low of $75.81, and 14.95% lower than its 52-week high of $106.74. The company’s market cap is $16.19 billion.

Based on its closing price on March 21, BioMarin Pharmaceutical has reported returns of -3.94% in the last week, 0.13% in the last month, and 1.34% in the last quarter. The company has reported returns of -8.82% in the last half year, 7.75% in the last year, and 6.61% year-to-date.

Revenue estimates

In its fourth quarter, BioMarin Pharmaceutical reported revenue of $353.21 million, a YoY (year-over-year) fall of 8.33% and $24.13 million lower than the consensus estimate. The company reported non-GAAP (generally accepted accounting principles) EPS of -$0.06, $0.18 lower than the consensus estimate.

Analysts expect BioMarin Pharmaceutical’s revenue to see YoY rises of 4.94% to $391.89 million in the first quarter, 11.10% to $414.22 million in the second quarter, 11.57% to $437.03 million in the third quarter, and 27.19% to $449.24 million in the fourth quarter of 2019. Analysts also expect BioMarin Pharmaceutical’s revenue to see YoY rises of 13.67% to $1.69 billion in 2019, 15.02% to $1.95 billion in 2020, and 16.09% to $2.26 billion in 2021. According to the company’s fourth-quarter earnings conference call, based on robust uptake in phenylketonuria indications in the US market and the anticipated regulatory approval for this drug in the European market, Palynziq is expected to prove to be the biggest market opportunity to date for the company.

Next, we’ll discuss analysts’ recommendations and projections for United Therapeutics.

Latest articles

McDonald’s (MCD) competition includes large international and national food chains as well as regional and local retailers of food products.

The restaurant industry is susceptible to a wide array of risks of macro and micro factors. As a huge global brand, McDonald’s faces several risks.

Google plans to offer a smart checking account along with Citigroup and Stanford Federal Credit Union. Tentatively called Cache, it could launch in 2020.

The proposed T-Mobile-Sprint merger agreement expired on November 1. Either company has the right to walk away from the transaction until a new date is set.

Since my last article about Nvidia (NVDA), the stock has risen from $196.86 to $208.57. I expect a further rise after today's earnings results.

TJX Companies (TJX) is scheduled to announce its fiscal 2020 third-quarter earnings results on November 19. Its third quarter ended on November 2.